Vanda Pharmaceuticals Inc. (VNDA)Healthcare | Biotechnology | Washington, United States | NasdaqGM
4.22 USD
-0.08
(-1.860%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:36 a.m. EDT
The investment case here is defined by a stark disconnect between the company's deteriorating financial reality and the aggressive optimism of retail traders. Fundamentally, the business is in freefall: revenue contracted by nearly 4% last year, profitability is nonexistent with negative operating margins, and the stock has lost roughly 70% of its value over the past nine years. The balance sheet is fragile, with cash burn outpacing inflows and no dividend to provide a floor. However, the short-term outlook is buoyed entirely by speculative positioning rather than operational strength. Options data reveals a massive 'call wall' at $7.00 and $10.00, indicating traders are pricing in a binary event—likely the FDA acceptance of the imsidolimab filing or the commercial launch of the motion sickness drug mentioned in recent headlines. This creates a high-risk, high-reward scenario where the stock could spike on news but lacks the underlying earnings power to sustain a higher valuation without significant proof of concept. The statistical forecast model offers almost no guidance, reflecting the noise inherent in such a volatile, small-cap biotech trade. Investors should view this as a pure event-driven gamble, not a fundamental recovery story. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.031153 |
| AutoETS | 0.031154 |
| MSTL | 0.031477 |
| AutoTheta | 0.034508 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.569 |
| Excess Kurtosis | 0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.369 |
| Revenue per Share | 3.627 |
| Market Cap | 255,152,528 |
| Forward P/E | 21.10 |
| Beta | 0.69 |
| Profit Margins | -127.41% |
| Website | https://www.vandapharma.com |
As of Oct. 10, 2026, 5:36 a.m. EDT: Speculators are overwhelmingly bullish, positioning heavy call volume and open interest at strikes significantly above the current price ($7.00 and $10.00 for December expiry), while put activity remains negligible. This asymmetry suggests a bet on a catalyst-driven rally rather than a defensive hedge.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.19924098 |
| Address1 | 2,200 Pennsylvania Avenue NW |
| Address2 | Suite 300E |
| All Time High | 33.44 |
| All Time Low | 0.45 |
| Ask | 5.78 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,003,150 |
| Average Daily Volume3 Month | 967,312 |
| Average Volume | 967,312 |
| Average Volume10Days | 1,003,150 |
| Beta | 0.688 |
| Bid | 4.37 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 3.642 |
| City | Washington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.22 |
| Current Ratio | 1.612 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.385 |
| Day Low | 4.2 |
| Debt To Equity | 10.369 |
| Display Name | Vanda Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -177,047,008 |
| Ebitda Margins | -0.82071996 |
| Enterprise To Ebitda | -0.61 |
| Enterprise To Revenue | 0.5 |
| Enterprise Value | 107,955,536 |
| Eps Forward | 0.2 |
| Eps Trailing Twelve Months | -4.63 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.068 |
| Fifty Day Average Change | -0.84800005 |
| Fifty Day Average Change Percent | -0.16732441 |
| Fifty Two Week Change Percent | -19.924099 |
| Fifty Two Week High | 9.94 |
| Fifty Two Week High Change | -5.72 |
| Fifty Two Week High Change Percent | -0.57545274 |
| Fifty Two Week Low | 4.2 |
| Fifty Two Week Low Change | 0.01999998 |
| Fifty Two Week Low Change Percent | 0.0047619003 |
| Fifty Two Week Range | 4.2 - 9.94 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,144,848,600,000 |
| Float Shares | 46,776,958 |
| Forward Eps | 0.2 |
| Forward P E | 21.099998 |
| Free Cashflow | -86,717,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 533 |
| Fullday Change | -0.119999886 |
| Fullday Change Percent | -2.8435993 |
| Fullday Price | 4.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.93738997 |
| Gross Profits | 202,215,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06776 |
| Held Percent Institutions | 0.87899 |
| Implied Shares Outstanding | 60,462,687 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia. |
| Long Name | Vanda Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 255,152,528 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_24545059 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -274,852,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 304,429,629 |
| Number Of Analyst Opinions | 5 |
| Open | 4.29 |
| Operating Cashflow | -142,331,008 |
| Operating Margins | -1.26282 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.23 |
| Phone | 202 734 3400 |
| Pre Market Change | -0.119999886 |
| Pre Market Change Percent | -2.8435993 |
| Pre Market Price | 4.1 |
| Pre Market Time | 1,792,062,014 |
| Previous Close | 4.3 |
| Price Hint | 4 |
| Price To Book | 1.1587039 |
| Price To Sales Trailing12 Months | 1.1827896 |
| Profit Margins | -1.2741101 |
| Quick Ratio | 1.401 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -0.0800004 |
| Regular Market Change Percent | -1.8604745 |
| Regular Market Day High | 4.385 |
| Regular Market Day Low | 4.2 |
| Regular Market Day Range | 4.2 - 4.385 |
| Regular Market Open | 4.29 |
| Regular Market Previous Close | 4.3 |
| Regular Market Price | 4.22 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 1,059,343 |
| Return On Assets | -0.22376 |
| Return On Equity | -0.77805 |
| Revenue Growth | -0.039 |
| Revenue Per Share | 3.627 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 60,462,687 |
| Shares Percent Shares Out | 0.1295 |
| Shares Short | 7,831,971 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,686,226 |
| Short Name | Vanda Pharmaceuticals Inc. |
| Short Percent Of Float | 0.1359 |
| Short Ratio | 8.08 |
| Source Interval | 15 |
| State | DC |
| Symbol | VNDA |
| Target High Price | 20.0 |
| Target Low Price | 5.75 |
| Target Mean Price | 11.75 |
| Target Median Price | 11.0 |
| Total Cash | 170,028,992 |
| Total Cash Per Share | 2.812 |
| Total Debt | 22,832,000 |
| Total Revenue | 215,720,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.4375 |
| Two Hundred Day Average Change | -2.2175002 |
| Two Hundred Day Average Change Percent | -0.34446606 |
| Type Disp | Equity |
| Volume | 1,059,343 |
| Website | https://www.vandapharma.com |
| Zip | 20,037 |